Email this article 
Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
- Authors: Cabanillas M.E.1, Takahashi S.2
-
Affiliations:
- The University of Texas M.D. Anderson Cancer Center
- Japanese Foundation for Cancer Research
- Issue: Vol 9, No 4 (2019)
- Pages: 49-61
- Section: REVIEW
- Published: 07.12.2019
- URL: https://ogsh.abvpress.ru/jour/article/view/453
- DOI: https://doi.org/10.17650/2222-1468-2019-9-4-49-61
- ID: 453
Cite item
Full Text
Abstract
.
About the authors
M. E. Cabanillas
The University of Texas M.D. Anderson Cancer Center
Author for correspondence.
Email: mcabani@mdanderson.org
ORCID iD: 0000-0002-5124-1811
Maria E. Cabanillas
Department of Endocrine Neoplasia & Hormonal Disorders
Houston, Texas
United StatesS. Takahashi
Japanese Foundation for Cancer Research
Email: fake@neicon.ru
ORCID iD: 0000-0002-5031-1953
Department of Medical Oncology, Cancer Institute Hospital
Tokyo
JapanReferences
Supplementary files
